The importance of medical cannabis in Australia

Introduction

The legalization of medicinal cannabis in Australia in 2016 initiated a rapid transformation in patient access and clinical practice. By June 2022, the Therapeutic Goods Administration (TGA) had recorded 258,926 prescription approvals under the Special Access Scheme Category B (SAS-B), driven by 5,284 active prescribers[1]. However, this rapid expansion has created a tension within the Australian medical community. There is a documented disconnection between restrictive specialist guidelines, which often recommend against use outside of clinical trials, and the high volume of general practitioner prescribing[2]. This review synthesizes the available literature on the clinical efficacy and patient outcomes of medicinal cannabis in Australia, focusing on chronic pain, pediatric epilepsy, psychiatric conditions, and the structural role of real-world evidence registries.

The Special Access Scheme and Real-World Evidence Frameworks

The Australian regulatory landscape relies heavily on the SAS-B pathway, which allows prescribers to access unapproved therapeutic goods for individual patients. Approvals under this scheme increased at an average rate of 208.55% per month between 2017 and 2022[1].

The Monitoring Gap and Registry Solutions

The speed of regulatory access has outpaced the infrastructure for clinical outcome tracking, creating a significant “monitoring gap”[1]. To address this deficit, Australian researchers and industry partners have established large-scale real-world evidence (RWE) registries. The QUEST initiative is a primary example, tracking 2,327 Australian patients newly prescribed oil-based medicinal cannabis[3]. A unique feature of the QUEST framework is its standardized pricing model, which reduces financial variability and facilitates future health economic evaluations in Australia[3].

Clinical trial designs within the SAS framework are also evolving to capture the complex effects of cannabis. Recent Australian palliative care protocols argue for measuring “total symptom distress” (using the Edmonton Symptom Assessment Scale) rather than isolated symptoms, reflecting the holistic symptom burden that patients seek to alleviate[4].

Public Perception and Pharmacovigilance

Patient demand often precedes clinical consensus. Social media discourse and internet search queries act as an early warning system for adverse drug reactions and self-medication patterns[5]. This digital pharmacovigilance helps explain the high patient demand for cannabis in Australia for conditions like post-traumatic stress disorder (PTSD) and chronic pain, even where formal clinical evidence is still emerging or classified as low quality[5].

Chronic Non-Cancer Pain and Opioid-Sparing Effects

Chronic non-cancer pain (CNCP) accounts for approximately 65% of all SAS-B approvals in Australia[2]. The 2025 global comparative baseline suggests that cannabinoids provide moderate efficacy for neuropathic and cancer-related pain, though the underlying evidence is frequently rated as low quality due to methodological inconsistencies[6].

Clinical Efficacy and Patient-Reported Outcomes

Within the Australian context, the TGA guidance notes that evidence for multiple sclerosis-related neuropathic pain achieves a moderate GRADE certainty, while evidence for other CNCP types remains low to moderate[7]. Meta-analyses of 102 studies indicate that patients using medicinal cannabis as an adjunctive therapy are more likely to achieve 30% and 50% pain reductions compared to placebo, though they also face 2.3 times the odds of experiencing an adverse event[7].

Real-world Australian data provides specific quantitative benchmarks for these improvements. In the QUEST initiative, the chronic pain cohort (n=1,598) reported a clinically meaningful reduction in pain severity (Cohen’s d = 0.65), with mean scores improving from 71.24 to 54.73 over three months[3]. Similarly, an observational study of 55 Australian patients at Releaf Clinics found that Brief Pain Inventory (BPI) severity scores decreased significantly from a mean of 5.54 at baseline to 4.33 at three months (p < 0.01, d = 0.66), alongside improvements in health-related quality of life (EQ-5D-5L improving from 0.54 to 0.67)[8].

However, the Australian POINT study (n=1,500) identifies a significant gap between patient-perceived relief and objective pain severity. While 16% of patients prescribed opioids for CNCP used adjunctive cannabis and reported greater perceived pain relief than non-users, these cannabis users actually recorded higher baseline pain severity and greater pain interference in daily life[9].

Opioid-Sparing Mechanisms and Evidence

The biological framework for the opioid-sparing effect is grounded in the synergistic interaction between cannabinoids and opioids, mediated by both CB1 and CB2 receptors[10]. Preclinical and pharmacological reviews indicate that delta-9-tetrahydrocannabinol (THC) can significantly reduce the minimum effective dose of opioids. Specifically, synergism can reduce the required dose of morphine by 55%, methadone by 75%, and codeine by 96%[11].

To provide international context for these opioid-sparing effects, the Canadian Canvas Rx registry tracked 757 chronic pain patients over 12 months. The proportion of participants reporting opioid consumption decreased from 40.8% at baseline to 23.9% at 12 months, with 50% of baseline opioid users ceasing opioids entirely[12]. This Canadian cohort also revealed sex-based differences in treatment response, with females experiencing significantly worse outcomes across pain intensity and interference domains compared to males[12]. In the UK Medical Cannabis Registry, a more modest 5.66% reduction in mean daily opioid consumption was recorded at 12 months (p = 0.039)[13].

Formulation and Delivery Impacts

The efficacy of these treatments is heavily dependent on formulation. The oral bioavailability of purified CBD and THC is naturally low (approximately 6% in a fasting state)[11]. However, the “food effect” and the use of lipid-based delivery systems (such as long-chain triglycerides) can increase bioavailability by 4 to 5 fold, bypassing first-pass metabolism via the lymphatic system[11]. This is highly relevant to the Australian context, where non-licensed preparations (flos and oils) are the primary products accessed via the SAS-B pathway[14].

Pediatric Refractory Epilepsy and Seizure Management

The use of purified cannabidiol (CBD) for pediatric refractory epilepsy represents one of the most rigorously studied applications of medicinal cannabis.

Clinical Efficacy of Purified CBD

High-quality randomized controlled trials, including those with significant Australian clinical leadership, have established the efficacy of 99% pure CBD (Epidiolex) for specific syndromes[15][16]. In a pivotal trial for Dravet syndrome, the median frequency of convulsive seizures per month decreased from 12.4 to 5.9 in the cannabidiol group, compared with a decrease from 14.9 to 14.1 in the placebo group (p=0.01)[15]. Furthermore, 5% of patients in the CBD group became entirely seizure-free during the 14-week trial[15].

Real-World Evidence and Modeling

Because traditional RCTs often exclude patients with complex comorbidities, researchers have applied Bayesian hierarchical modeling to validate small-N pediatric epilepsy data. Using data from the UK Project Twenty21 (T21) registry as a benchmark for Australian registry analysis, Bayesian models demonstrated an 86% average reduction in monthly seizure frequency among a cohort of 20 children with intractable epilepsy treated with whole-plant cannabis products[17].

Regarding neurodevelopmental outcomes, no longitudinal data addressing the long-term cognitive or developmental impacts of CBD interventions on pediatric cohorts was identified in the reviewed literature. The primary RCTs were limited to 14-week durations, which is insufficient to measure long-term neurodevelopment[15].

Psychiatric Outcomes in Anxiety and PTSD

The application of medicinal cannabis for psychiatric conditions, particularly anxiety and PTSD, shows promising short-term results but highlights significant discrepancies between clinical trial protocols and real-world prescribing.

Symptom Severity and Dosing Discrepancies

In the Australian QUEST initiative, patients with diagnosed anxiety conditions reported clinically meaningful improvements (d = 0.72) over a three-month period using oil-based formulations[3].

A critical finding in the literature is the dosing discrepancy between real-world practice and RCTs. Data from Canadian clinics reveals that the average daily CBD dose in real-world settings is 11.5 mg, which is substantially lower than the doses (up to 1000 mg) typically utilized in experimental trials[18]. Despite this low dose, patients with moderate-to-severe baseline symptoms achieved a 1.3 to 2.5 point decrease on the Edmonton Symptom Assessment System-revised (ESAS-r) scale[18]. Notably, patients with only mild symptoms at baseline showed no improvement, indicating a severity-dependent response threshold[18].

Administration Routes and Longitudinal Plateaus

Comparative international registry data provides insights into how administration routes affect psychiatric outcomes. In the UK Medical Cannabis Registry, patients prescribed dried flower formulations (either alone or combined with oils) showed greater improvements in anxiety (GAD-7) and sleep quality (SQS) compared to those prescribed oils alone[13]. This is a vital contrast to Australian data, which predominantly reports on oil-based formulations[3].

Longitudinal tracking suggests that psychiatric benefits may plateau over time. In a UK cohort of osteoarthritis patients, anxiety symptoms improved significantly at 1 and 3 months (p < 0.05) but did not maintain statistical significance at the 6 or 12-month follow-ups[19].

Comparative Registry Outcomes

Notes: “Not reported” indicates the specific metric was not published in the reviewed literature for that cohort. UKMCR = UK Medical Cannabis Registry. BPI = Brief Pain Inventory. GAD-7 = Generalized Anxiety Disorder-7.

Integration and Emerging Patterns

A consistent pattern across the literature is the tension between the ecological validity of real-world evidence and the internal validity of randomized controlled trials. RCTs often exclude patients with comorbidities, which eliminates up to 58.7% of chronic pain patients and over 89% of anxiety/PTSD patients seen in actual clinical practice[17]. Consequently, Australian regulatory frameworks have adapted by relying on large-scale observational registries (like QUEST) to track the holistic symptom burden of patients using non-licensed preparations[4][3].

Furthermore, the literature highlights a transition in delivery methods. While inhaled dried flower may offer superior rapid relief for anxiety and sleep[13], longitudinal clinical cohorts show patients gradually gravitating away from dried cannabis toward oil-based formulations or combination therapies over a 12-month period[12]. The efficacy of these oral oils is heavily modulated by the food effect and lipid-based vehicles, which are required to overcome the naturally low 6% bioavailability of fasting oral ingestion[11].

Gaps and Limitations

Several critical gaps remain in the reviewed literature:

• Neurodevelopmental Data: No longitudinal data assessing the neurodevelopmental outcomes of pediatric patients treated with purified CBD for refractory epilepsy was identified.
• Long-Term Psychiatric Efficacy: Evidence for anxiety and PTSD is largely limited to 3-month windows in the Australian context. International data suggests these benefits may lose statistical significance by 6 to 12 months[19].
• Methodological Limitations of Registries: The RWE registries (QUEST, Canvas Rx, UKMCR) suffer from high attrition rates (up to 89.6% at 12 months in the Canadian cohort)[12]. This introduces significant survivorship bias, where long-term efficacy data only reflects the subset of patients who found the treatment tolerable and effective.
• Lack of Placebo Controls in RWE: The observational nature of the Australian SAS-B registry data prevents definitive causal attribution of symptom improvements to cannabis, particularly given the high placebo response rates common in pain and psychiatric trials[19].

Conclusions

The literature provides the following insights regarding the clinical efficacy and patient outcomes of medicinal cannabis in Australia:

Opioid-Sparing Effects and Pain Severity: Australian cohorts report clinically meaningful reductions in pain severity (d = 0.65 to 0.66) over three months using primarily oil-based formulations[3][8]. While the biological mechanism for opioid-sparing is well-established through CB1/CB2 receptor synergism (capable of reducing codeine requirements by 96% in models)[11][10], Australian-specific longitudinal data on opioid cessation is limited. International registries suggest up to 50% of baseline opioid users may cease usage at 12 months[12].

Pediatric Refractory Epilepsy: Purified CBD (Epidiolex) significantly reduces convulsive seizure frequency (from 12.4 to 5.9 per month) in syndromes like Dravet[15]. Bayesian modeling of real-world data suggests whole-plant extracts can achieve up to an 86% reduction in seizures for small cohorts[17]. However, data on long-term neurodevelopmental outcomes is absent from the reviewed literature.

PTSD and Anxiety: Australian patients report significant short-term improvements in anxiety (d = 0.72) using real-world doses (e.g., 11.5 mg/day) that are vastly lower than those used in clinical trials[3][18]. Comparative data indicates that inhaled dried flower may offer superior psychiatric symptom relief compared to oils[13], though evidence suggests anxiety improvements may plateau after six months[19].

Pharmacovigilance and the SAS Framework: The Australian SAS-B framework has experienced exponential growth, reaching over 258,000 approvals by mid-2022[1]. To bridge the monitoring gap caused by this rapid expansion, Australia relies on structured RWE registries (like QUEST) that utilize standardized pricing and holistic symptom burden assessments to track clinical outcomes and safety in real-time[4][3].

References

1. TGA SAS-B Approval Data Analysis (2022). Int J Environ Res Public Health.
2. GP Prescribing Patterns for Medicinal Cannabis (2021). Aust J Gen Pract.
3. The QUEST Initiative: Australian Real-World Evidence (2023). PLoS ONE.
4. Palliative Care Protocol Design (2019). BMC Palliat Care.
5. Digital Pharmacovigilance and Patient Demand (2022). PLoS ONE.
6. Global Cannabinoid Efficacy Baseline (2025). Biomedicines.
7. TGA/NPS Evidence Summary: Chronic Non-Cancer Pain. NPS MedicineWise.
8. Releaf Clinics Observational Study (2023). Cannabis Cannabinoid Res.
9. The Australian POINT Cohort Study. NDARC.
10. Cannabinoid-Opioid Receptor Interactions (2019). Br J Pharmacol.
11. Pharmacokinetics and Bioavailability of Cannabinoids (2021). Drugs.
12. Canvas Rx Registry: Canadian Chronic Pain Cohort (2021). Can J Anaesth.
13. UK Medical Cannabis Registry Outcomes (2024). Neuropsychopharmacol Rep.
14. Australian SAS-B Product Composition Analysis (2021). Molecules.
15. Cannabidiol in Dravet Syndrome RCT (2017). N Engl J Med.
16. Cannabidiol for Epilepsy: Efficacy Review (2018). F1000Research.
17. Bayesian Modeling in Pediatric Epilepsy (2022). Front Psychiatry.
18. Real-World CBD Dosing in Canadian Clinics (2021). J Cannabis Res.
19. Longitudinal Psychiatric Outcomes in Osteoarthritis Cohort (2024). J Pain Palliat Care Pharmacother.